Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary

Onkologie

Volumn 32, Issue 4, 2009, Pages 162-166

  Schuette, Katharina ^a   Folprecht, Gunnar ^a   Kretzschmar, Albrecht ^b   Link, Hartmut ^c   Koehne, Claus Henning ^d   Gruenwald, Viktor ^e   Stahl, Michael ^f   Huebner, Gerdt ^g  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b HELIOS KLINIKUM BERLIN BUCH   (Germany)

^c Westpfalz Klinikum GmbH   (Germany)

^d KLINIKUM OLDENBURG   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f KLINIKEN ESSEN MITTE   (Germany)

^g SANA KLINIKUM OFFENBACH   (Germany)

Author keywords

Capecitabine; Carcinoma of unknown primary; Chemotherapy; CUP; Oxaliplatin; Phase II study

Indexed keywords

CAPECITABINE; LACTATE DEHYDROGENASE; OXALIPLATIN;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; INFECTION; LEUKOPENIA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNDIFFERENTIATED CARCINOMA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 65349170190     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000201125     Document Type: Article

References (24)

1. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N: Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000;18:3101-3107.
2. Greco FA, Burris HA, III, Litchy S, Barton JH, Bradof JE, Richards P, Scullin DC Jr, Erland JB, Morrissey LH, Hainsworth JD: Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002;20: 1651-1656.
3. Huebner G, Steinbach S, Kohne CH, Stahl M, Kretzschmar A, Eimermacher A, Link H, German CUP Study Group: Paclitaxel (P)/carboplatin (C) versus gemcitabine (G)/vinorelbine (V) in patients with adeno- or undifferentiated carcinoma of unknown primary (CUP) - a randomized prospective phase-II-trial. J Clin Oncol (meet abstr) 2005; 23:4089.
4. Cassidy J, Clarke S, az-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Saltz L: Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008;26:2006-2012.
5. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ: Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007;25:4217-4223.
6. Arnold D, Hacker U: Palliative Chemotherapie des Kolonkarzinoms. Onkologie 2007; 30(suppl 2): 13-17.
7. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36-46.
8. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jager E: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008;26:1435-1442.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
10. Kang Y, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Philco M, Suarez T, Santamaria J: Randomized phase III trial of capecitabine/ cisplatin (XP) vs. continuous infusion of 5-FU/ cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): efficacy and safety results. J Clin Oncol (meet abstr) 2006;24: LBA4018.
11. Riess H, Pelzer U, Stieler J, Schwaner I, Heil G, Gorner M, Molle M, Hilbig A, Dorken B, Oettle H: A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer - CONKO 003. J Clin Oncol (meet abstr) 2007;25:4517.
12. Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P: Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol 2004;15:467-473.
13. Nehls O, Klump B, Arkenau HT, Hass HG, Greschniok A, Gregor M, Porschen R: Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. Br J Cancer 2002;87:702-704.
14. Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhofer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B: Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008;98:309-315.
15. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van HG, Verma S, Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline- pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20: 2812-2823.
16. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
17. Pectasides D, Pectasides M, Farmakis D, Bountouroglou N, Nikolaou M, Koumpou M, Mylonakis N, Kosmas C: Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study. Ann Oncol 2003;14:537- 542.
18. Thuss-Patience PC, von Minckwitz G, Kretzschmar A, Loibl S, Schaller G, Dorken B, Reichardt P: Oxaliplatin and 5-fluorouracil for heavily pretreated metastatic breast cancer: a preliminary phase II study. Anticancer Drugs 2003;14:549-553.
19. Sundar S, Symonds RP, Decatris MP, Kumar DM, Osman A, Vasanthan S, O'Byrne KJ: Phase II trial of oxaliplatin and 5-fluorouracil/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol Oncol 2004;94:502-508.
20. Saito J, Nakai Y, Saijo Y, Nukiwa T, Koinumaru S, Matsuura Y, Aso N, Yamane Y, Tsukamoto T, Sayama T, Nakabayashi T: A phase II trial of oral UFT plus cisplatin (CDDP) in patients with nonsmall cell lung cancer (NSCLC). Lung Cancer 2001; 31:285-293.
21. Bidoli P, Zilembo N, Cortinovis D, Mariani L, Isa L, Aitini E, Cullura D, Pari F, Nova P, Mancin M, Formisano B, Bajetta E: Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Ann Oncol 2007;18:461-467.
22. Monnet I, Brienza S, Hugret F, Voisin S, Gastiaburu J, Saltiel JC, Soulie P, Armand JP, Cvitkovic E, de CH: Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques. Eur J Cancer 1998;34:1124-1127.
23. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, Fizazi K: Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 2002; 20:4679-4683.
24. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, Greco FA: Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol 2007;25:1747-1752.